Ivermectin is NOT indicated for viral respiratory infections, including COVID-19
Ivermectin should not be used for the treatment or prevention of COVID-19 or other viral respiratory infections outside of clinical trials. The highest quality evidence—from the Infectious Diseases Society of America (IDSA) 2024 guidelines—provides a clear recommendation against its use based on comprehensive analysis of randomized controlled trials 1.
Evidence-Based Rationale
For Hospitalized Patients with COVID-19
The IDSA guidelines demonstrate that ivermectin:
- Does not reduce mortality (RR: 0.54; 95% CI: 0.28-1.03; moderate certainty of evidence)
- Does not reduce need for mechanical ventilation (RR: 0.40; 95% CI: 0.13-1.27; low certainty)
- Does not improve symptom resolution at day 7 (RR: 1.07; 95% CI: 0.69-1.65; very low certainty)
- Does not enhance viral clearance (RR: 1.21; 95% CI: 0.77-1.90; very low certainty)
The guideline panel suggests against ivermectin for hospitalized patients with very low certainty of evidence due to study limitations and imprecision 1.
For Outpatient/Ambulatory Patients with COVID-19
The evidence is even clearer for outpatients:
- Does not reduce mortality (RR: 0.83; 95% CI: 0.50-1.37; HIGH certainty of evidence)
- Does not prevent hospitalization (RR: 0.85; 95% CI: 0.65-1.11; moderate certainty)
- Does not improve viral clearance at day 7 (RR: 1.11; 95% CI: 0.85-1.44; very low certainty)
- Does not reduce symptom severity (RR: 0.72; 95% CI: 0.44-1.17; moderate certainty)
The guideline panel recommends against ivermectin for outpatients with moderate certainty of evidence 1.
For Prevention of SARS-CoV-2 Infection
The IDSA guidelines made a conditional recommendation against ivermectin for prevention, with insufficient evidence to demonstrate benefit 1.
Supporting Research Evidence
A comprehensive 2026 meta-analysis of 40 RCTs involving 23,243 participants reinforced these findings:
- No reduction in mortality for hospitalized patients (RR 0.94; 95% CI 0.74-1.20) or outpatients (RR 0.88; 95% CI 0.55-1.42)
- No reduction in SARS-CoV-2 infection rate for prevention (RR 0.37; 95% CI 0.12-1.20)
- No difference in adverse events 2
The 2021 Cochrane systematic review similarly concluded that "reliable evidence available does not support the use of ivermectin for treatment or prevention of COVID-19 outside of well-designed randomized trials" 3.
Critical Methodological Issues
Multiple studies included in the evidence base had significant methodological flaws:
- Inadequate randomization (allocation by odd/even days or registration numbers)
- Lack of blinding of study personnel
- High risk of bias in key trials
- Substantial heterogeneity in dosing regimens (100-400 mcg/kg/day for 1-7 days) 1
FDA-Approved Indications
The FDA label for ivermectin (Stromectol) specifies approval only for parasitic infections—specifically strongyloidiasis and onchocerciasis. There is no FDA approval for viral respiratory infections 4.
Safety Considerations
While ivermectin is generally well-tolerated at antiparasitic doses, the guidelines note:
- Cannot exclude potential for serious adverse events in COVID-19 patients (RR: 3.10; 95% CI: 0.54-17.89 for hospitalized; moderate certainty)
- Rare but serious risk of encephalopathy in patients co-infected with Loa loa
- Potential drug interactions, including increased INR when co-administered with warfarin 1, 4
Clinical Bottom Line
Do not prescribe ivermectin for COVID-19 or other viral respiratory infections in routine clinical practice. The evidence consistently demonstrates no meaningful benefit for mortality, hospitalization, symptom resolution, or viral clearance—the outcomes that matter most for patient morbidity, mortality, and quality of life. Use evidence-based therapies with proven efficacy instead.